GLS and Keratoconjunctivitis sicca: This showed the pivotal role of glutamine and its upstream key enzyme GLS1 in dry eye treatment, elucidated the molecular foundation of MSCs and Tβ4 combination therapy, and unveiled potential novel targets for dry eye treatment.